Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...
The Week

FACT CHECK: Does wearing a saree cause cancer?

It starts with friction but does it end in cancer? Medical literature does document cases of what is informally referred to ...

Woman, 26, Had Excessive Itching but Was Told 'It's Just One of Those Things.' She Then Self-Diagnosed Her Cancer (Exclusive)

A young woman suffered from excessive itching and was dismissed by multiple doctors, before she eventually self-diagnosed ...